RECRUITING

A Study to Evaluate the Efficacy and Safety of NBI-1070770 in Adults With Major Depressive Disorder

Description

To evaluate the efficacy, safety, and tolerability of NBI-1070770 compared to placebo on improving symptoms of depression in participants with major depressive disorder (MDD).

Conditions

Major Depressive Disorder
Talk to us

Related Conditions:

Major Depressive Disorder

Study Overview

On this page

Study Details

Study overview

To evaluate the efficacy, safety, and tolerability of NBI-1070770 compared to placebo on improving symptoms of depression in participants with major depressive disorder (MDD).

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of NBI-1070770 in Adults With Major Depressive Disorder

A Study to Evaluate the Efficacy and Safety of NBI-1070770 in Adults With Major Depressive Disorder

Condition
Major Depressive Disorder
Intervention / Treatment

-

Contacts and Locations

Little Rock

Neurocrine Clinical Site, Little Rock, Arkansas, United States, 72211

Rogers

Neurocrine Clinical Site, Rogers, Arkansas, United States, 72758

Lemon Grove

Neurocrine Clinical Site, Lemon Grove, California, United States, 91945

Long Beach

Neurocrine Clinical Site, Long Beach, California, United States, 90806

Hollywood

Neurocrine Clinical Site, Hollywood, Florida, United States, 33024

Maitland

Neurocrine Clinical Site, Maitland, Florida, United States, 32751

Decatur

Neurocrine Clinical Site, Decatur, Georgia, United States, 30030

Savannah

Neurocrine Clinical Site, Savannah, Georgia, United States, 31405

Gaithersburg

Neurocrine Clinical Site, Gaithersburg, Maryland, United States, 20877

Dayton

Neurocrine Clinical Site, Dayton, Ohio, United States, 45439

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Participant is pregnant or breastfeeding or plan to become pregnant during the study.
  • * Participant has an unstable medical condition or unstable chronic disease.
  • * Participant has a history of neurological abnormalities.
  • * Participant has a current or prior psychiatric disorder diagnosis that was the primary focus of treatment other than MDD.
  • * Participant's depressive symptoms have previously demonstrated nonresponse to an adequate course of treatment with electroconvulsive therapy.
  • * Participant has an alcohol or substance use disorder.

Ages Eligible for Study

18 Years to 65 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Neurocrine Biosciences,

Clinical Development Lead, STUDY_DIRECTOR, Neurocrine Biosciences

Study Record Dates

2025-12